Anti-PSMA sEV mimetics (EMs), created by genetically modifying U937 cells and extruding them, have demonstrated their potential for PCa treatment in both in vitro and in vivo studies [184]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.